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Background: Recent studies showed that diffuse large B-cell lymphoma (DLBCL) could be classified into germinal
centre B cell-like (GCB) and non-germinal centre B cell-like (non-GCB) phenotypes according to CD10,Bcl-6 and
MUM1 expression. But primary gastrointestinal DLBCL has rarely been studied. This study was aimed to investigate
the relationship between immunophenotypic classification, therapeutic outcomes and the prognosis of patients
with primary gastrointestinal DLBCL.
Methods: Between 1998 and 2010, there were 151 patients studied at Shanghai Renji Hospital with a
histopathological diagnosis of primary gastrointestinal DLBCL. Immunohistochemistry was performed using EnVision
methods for CD10, BCL-6 and MUM1. The clinicopathologic features and follow-up data were analyzed by the
Kaplan-Meier method, log-rank test and χ2 test.
Results: According to the expression of CD10, BCL-6 and MUM1, 31.8 % (48/151) of the cases belonged to the GCB
subtype and 68.2 % (103/151) belonged to the non-GCB subtype. There was a significant difference of local lymph
node metastasis between the GCB and non-GCB groups (P< 0.05). Patients in the GCB group had a better survival
rate than those in the non-GCB group (5-year survival rate, 65.2 % vs 36.4 %, P< 0.05). In the GCB group, there was
no significant difference in survival rates in patients receiving R-CHOP and CHOP therapy (P> 0.05). In the non-GCB
group, the survival rate in patients treated with R-CHOP therapy was significantly longer than those treated with
CHOP therapy (5-year survival rate, 62.8 % vs 30.8 %, P< 0.05).
Conclusions: The immunophenotype classification of gastrointestinal DLBCL, which is closely related to local lymph
node metastasis, is found to have prognostic significance. Immunophenotype classification is also useful in selecting
the chemotherapy protocol.
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PrognosisBackground
In 2004, Hans et al found that according to the expres-
sion of CD10, BCL-6 and MUM-1, diffuse large B-cell
lymphoma (DLBCL) could be categorized into two sub-
types: germinal centre B cell-like (GCB) and non-
germinal centre B cell-like (non-GCB) phenotypes. This
immunophenotype classification could be used to pre-
dict the survival rate in patients with DLBCL [1].* Correspondence: niyin@yahoo.com
†Equal contributors
1Department of General Surgery, Ren Ji Hospital Medical College of Shanghai
Jiao Tong University, Dongfang Road 1630, Shanghai 200127, China
Full list of author information is available at the end of the article
© 2012 Zizhen et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orHowever, primary gastrointestinal DLBCL has rarely
been studied with the immunophenotype classification.
The gastrointestinal tract is the most common extra-
nodal site for lymphoma and represents 30-40 % of all
extranodal sites. All histopathological categories of nodal
lymphomas may also arise in the gastrointestinal tract,
but DLBCL is the most common histopathological sub-
type, which accounts for about 50 %. However, there is
still debate on the diagnosis, treatment and prognosis of
gastrointestinal DLBCL. Thus, the main goals of the
current study were: (1) to evaluate if immunohistochem-
ial staining with antibodies of CD10, BCL-6 and MUM1
could define distinct, clinically significant subgroups ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and










Figure 1 Classification of gastrointestinal DLBCL. According to
CD10, Bcl-6 and MUM1 expression, 151 cases were classified into
GCB and non-GCB types.
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groups had prognostic significance for patients with
gastrointestinal DLBCL; (3) to assess the therapeutic
outcomes of the different immunophenotype subgroups.
Methods
Patients
Between 1998 and 2010, there were 156 patients studied
at Shanghai Renji Hospital with a histopathological diag-
nosis of primary gastrointestinal DLBCL. All the patients
were enrolled in the course of the study that was
approved by the local ethic committee. Written
informed consent was obtained. Patient follow-up oc-
curred through May 8, 2011. There were 151 patients
followed up (96.8 %) and 5 patients lost. The median age
was 63 years (range 15–81); and there were 91 men
(60.3 %) and 60 women (39.7 %). All cases fulfilled the
clinical criteria of primary gastrointestinal lymphoma
presented by Dawson [2]. Among the 151 cases, 66.2 %
(100/151) involved the stomach (48, gastric antrum; 35,
gastric corpora; 10, gastric fundus; 7, multifocal) and
33.8 % (51/151) involved the intestine (21, ileocecal
junction; 15, small intestine; 9, colon; 6, multifocal).
All 151 patients were pathologically diagnosed by sur-
gery or endoscopic biopsy. Forty patients underwent rad-
ical or palliative resection only, 28 were treated with
chemotherapy only, and 83 with surgery plus chemother-
apy. Among the 111 patients treated with chemotherapy,
81 patients received CHOP-like therapy (CTX 600 mg/
m2, d1; ADM 50 mg/m2 or EADM 70 mg/m2, d1; VCR
2 mg, d1; PRED 80 mg/m2, d1-5) and 30 patients
received rituximab plus CHOP (R-CHOP) therapy. The
median follow-up time was 30 months (range, 3 to
112 months).
Immunohistochemical investigation
Immunohistochemical staining was performed with a
two-step EnVision method. All tissue biopsies were fixed
routinely in 10 % buffered formalin, embedded in paraf-
fin, and cut into 4-μm sections. Following deparaffiniza-
tion, heat-induced antigen retrieval techniques were
used. Endogenous peroxidase activity was then blocked
with 0.5 % H2O2. After being washed in Trisbuffered sa-
line (TBS), the sections were stained with antibodies to
CD10 (RTU-CD10-270-qh, Novocastra), BCL-6 (RTU-
BCL-6-564-qh, Novocastra) and MUM1 (GM725902,
DAKO). The reaction was carried out at room
temperature overnight. After the sections were washed in
TBS again, the secondary antibodies EnvisionTM
(mouse) (K4001, DAKO) or EnvisionTM (rabbit) (K4002,
DAKO) were dropped. The cell nucleus was restained
with hematoxylin after Diaminobenzidine (DAB) showed
color. Cases were considered positive if 30 % or more of
the tumor cells were stained.Immunohistochemical scoring
The intensity of the staining as well as the percentage of
positive cells was recorded. Staining intensity was scored
from 0 to 3+; the intensity score was established as fol-
lows: 0, if absence of staining was observed; 1+, if >25 %
of the tumor cells had weak staining; 2+, if tumor cells
had moderate staining; and 3+ if tumor cells had strong
staining. Tumors with 1+, 2+, and 3+ expression were
interpreted as positive and tumors with no expression
(0 score) were interpreted as negative.
Classification of DLBCL
Using the Hans algorithm, according to CD10, BCL-6
and MUM1 expression, 151 cases were classified into
two subtypes: GCB and non-GCB (Figure 1).
Statistical analysis
The analysis was conducted with SPSS16.0 software.
Characteristics of the two groups were compared using
the χ2 test. The Kaplan-Meier method was used to esti-
mate the survival distributions. The log-rank test was
used to compare the survival distributions. All statistical
tests were two-sided, and P< 0.05 was considered statis-
tically significant.
Results
At the time of analysis, 78 patients (51.7 %) were alive
and 73 patients (48.3 %) had died. The overall 2, 3 and
5-year survival rates were 64.4 %, 56.2 % and 45.6 %, re-
spectively. Expression of CD10 was observed in 22.5 %
(34/151) of the patients, BCL-6 in 70.2 % (106/151), and
MUM1 in 72.8 % (110/151). According to the results
from immunohistochemical staining, 31.8 % (48/151) of
the cases were classified as GCB subtype and 68.2 %
(103/151) as non-GCB subtype.
The pathological parameters of the cases treated with
surgery included tumor size, infiltrate depth and local
lymph node metastasis. Statistical analysis showed that
immunophenotype classification was not associated
with tumor size and infiltrate depth. The mean diam-
eter of tumors with two subtypes were 8.1±3.4 cm and
Table 1 The infiltrate depth of tumors in GCB and
non-GCB subtypes





GCB 10(27.0 %) 27(73.0 %) 1.468 0.232
Non-GCB 15(17.4 %) 71(82.6 %)
Table 3 Immunohistochemical stain results and their
effect on survival by univariate analysis
No. (%) 5-year survival
rate (%)
χ2 P
CD10 Negative 77.5 % (117/151) 40.2 % 3.501 0.061
Positive 22.5 % (34/151) 62.4 %
Bcl-6 Negative 29.8 % (45/151) 36.1 % 1.328 0.249
Positive 70.2 % (106/151) 49.5 %
MUM1 Negative 27.2 % (41/151) 45.8 % 1.713 0.191
Positive 72.8 % (110/151) 42.6 %
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tumors were localized within submucosa in 27.0 % (10/
37) of GCB cases and 17.4 % (15/86) of non-GCB
cases (χ2 = 1.468,P> 0.05) (Table 1). However, the sig-
nificant association of subclassification and local lymph
node metastasis was observed. There were 40.5 % (15/
37) of GCB cases and 65.1 % (56/86) of non-GCB
cases with local lymph node metastasis, respectively
(χ2 = 6.403,P< 0.05) (Table 2).
Univariate analysis of the expression of each protein
and its relationship to survival are shown in Table 3.
The 5-year survival rate was not significantly different be-
tween patients with CD10 positive and negative, BCL-6
positive and negative, or MUM1 positive and negative.
However, survival analysis demonstrated that patients of
GCB subtype had a significantly better survival rate com-
pared with patients of non-GCB subtype (5-year survival
rate, 65.2 % vs 36.4 %, χ2= 7.371,P< 0.05) (Figure 2).
In univariate analysis, chemotherapy was associated
with improved survival. Patients treated with chemother-
apy showed superior survival rates when compared to
those treated with non-chemotherapy treatment (5-year
survival rate, 48.8 % vs 34.6 %, χ2 = 8.440, P< 0.05)
(Figure 3). The survival rate was not significantly differ-
ent between patients treated with surgical and non-
surgical treatment (5-year survival rate, 60.5 % vs 54.8 %,
χ2 = 0.036, P> 0.05). Among the 111 patients who
received chemotherapy, the survival rate for patients in
the R-CHOP group was significantly longer than those in
the CHOP group (5-year survival rate, 68.4 % vs 43.2 %,
χ2 = 5.430, P< 0.05) (Figure 4).
We then compared the survival rate of patients treated
with CHOP or R-CHOP therapy in different immuno-
phenotype groups. In the GCB group, the 5 patients
treated with R-CHOP therapy all survived. But there was
no significant difference in the survival rate between the
patients who received R-CHOP and CHOP therapyTable 2 Local lymph nodes metastasis in GCB and
non-GCB subtypes
local lymph nodes metastasis χ2 P
(+) (−)
GCB 15(40.5 %) 22(59.5 %) 6.403 0.017
Non-GCB 56(65.1 %) 30(34.9 %)(χ2 = 1.981, P> 0.05). In the non-GCB group, the sur-
vival rate of patients treated with R-CHOP therapy was
significantly longer than those with CHOP therapy (5-
year survival rate, 62.8 % vs 30.8 %, χ2 = 6.140, P< 0.05).
Discussion
DLBCL is the most common type of all non-Hodgkin’s
lymphomas (NHLs) and accounts for 30 % to 40 % of
new diagnoses. DLBCL is defined as diffuse prolifera-
tions of large neoplastic mature B cells, and it is, how-
ever, recognized that this definition comprises a group
of morphologically, immunohistochemically, and clinic-
ally heterogeneous tumors rather than one single entity.
According to the literature, 27-48 % cases of non-
Hodkin’s lymphoma are extranodal lymphoma. The
gastrointestinal tract is the most common extranodal site
of lymphoma, and the most common type of gastrointes-
tinal lymphoma is DLBCL [3]. Yet there is hardly any
research specifically focused on gastrointestinal DLBCL.
The original criteria for primary gastrointestinal
DLBCL are: (1) pathologically confirmed diagnosis of
DLBCL, according to the WHO classification; (2) clinic-
ally confirmed diagnosis of primary gastrointestinal
lymphoma. In 1961, Dawson et al. proposed clinical cri-
teria for distinguishing primary gastrointestinal lymph-
oma from secondary involvement. These criteria include:
a) absence of peripheral lymphadenopathy at the time of
presentation, b) lack of enlarged mediastinal lymph-
nodes, c) a normal total WBC and differential, d) pre-
dominance of the gastrointestinal lesion at the time of
laparotomy with only the lymph nodes in the immediate
vicinity being obviously affected, e) the liver and spleen
not showing any lymphomatous involvement [2]. The
151 cases in our study fulfilled all these criteria.
During the past few years, several studies with cDNA
microarrays have shown that DLBCL can be divided into
three types according to the different stages of tumori-
genic B-cell [4–9]. One of the three types, GCB DLBCL,
expresses genes characteristic of normal GCB cells
(expressing CD10, BCL-6, LMO-2, A-myb, BCL-7A, etc)
and is associated with a good outcome after multiagent
chemotherapy. Another type, activated B cell-like (ABC)
Figure 2 Kaplan-Meier curve of OS for patients of GCB (blue) and non-GCB (green). Patients of GCB lived longer than those of non-GCB
(P< 0.05).
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B cells (expressing IRF4, FLIP BCL-2, etc) and is asso-
ciated with a poor clinical outcome. The third type,
DLBCL co-express GCB and ABC DLBCL, is referred toFigure 3 Kaplan-Meier curve of OS for patients treated with chemoth
chemotherapy lived longer than those treated with non-chemotherapy (P<as type 3. The type 3 group is heterogeneous and not
well defined, but has a poor outcome similar to the ABC
group. The study by Hans et al [1] showed that the 5-
year overall survival rate for the GCB group is more thanerapy (blue) and non-chemotherapy (green). Patients treated with
0.05).
Figure 4 Kaplan-Meier curve of OS for patients treated with CHOP (blue) and R-CHOP (green) postoperative chemotherapy. Patients
treated with R-CHOP lived longer than those treated with CHOP chemotherapy (P< 0.05).
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groups. The 5-year overall survival rate for ABC and type
3 is about 30 %.
Because gene expression technology is not currently
available for routine clinical use and the technology
requires fresh tissue with an adequate amount of RNA,
the clinical application of classification of DLBCL by
cDNA microarrays is restricted. In 2004, Hans et al
found that tissue microarrays (TMA) could be used in
the classification of DLBCL. The GCB and non-GCB
subtypes can be accurately predicted according to the
expression pattern of CD10, BCL-6 and MUM1. Com-
pared with the cDNA microarray, the immunostain
panel reproduced the gene expression results in 71 % of
GCB and 88 % of non-GCB cases and predicted for
survival in a similar manner. Results suggested that
DLBCL can be divided into GCB and non-GCB sub-
types by immunohistochemistry and that the non-GCB
subtype probably included ABC type and type 3 [1].
Recent studies have demonstrated that the immuno-
phenotype is an important independent prognostic fac-
tor [10,11].
In the current study, we aimed to test the expression
of CD10, BCL-6 and MUM1 by immunohistochemical
staining. CD10 is a membrane-associated, neutral endo-
peptidase, which is expressed in a variety of human tis-
sue, but has a restricted expression in the germinal
center cells of reactive lymphoid tissue [12]. BCL-6 is azinc-finger protein that acts as a transcriptional repressor
and is expressed in germinal center B cells and a subset of
CD4+ T cells [13–16]. CD-10 and BCL-6, regarded as
the important markers in diagnosing GCB DLBCL, both
express in normal GCB cells. Furthermore, many studies
have suggested that expression of CD10 and BCL-6 in
DLBCL predicts better overall survival rates. MUM1 is a
lymphoid-specific member of the interferon regulatory
factor family of transcription factors [17]. MUM1 is nor-
mally expressed in plasma cells and a minor subset of
germinal center cells. Expression of MUM1 may denote
the final step of germinal center B-cell differentiation
with subsequent B-cell maturation toward plasma cells
[18]. It appears that MUM1 has the potential to be a
marker of the non-GCB phenotype.
We found that, of 151 cases of gastrointestinal DLBCL,
48 (31.8 %) were classified as GCB and 103 cases
(68.2 %) as non-GCB. The study on the relationship be-
tween immunophenotype classification and pathological
parameters indicated that patients of non-GCB subtype
were more likely to suffer from local lymph node metas-
tasis than patients of GCB subtype, while the two sub-
types did nothing with tumor size and infiltrate depth.
Our study also showed that the survival rate of patients
in the GCB group was obviously longer than that of
patients in non-GCB group. These results were similar
to those of Hans’s study which focused on both nodal
and extranodal DLBCL [1]. The results above indicate
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to predict the prognosis of the primary gastrointestinal
DLBCL patients.
During the past 10 years, the treatment of PGI-DLBCL
was still controversial. In a current study, chemotherapy
was associated with improved survival rates while surgi-
cal treatment did not significantly affect it. Most previ-
ous studies have suggested that chemotherapy or surgery
plus postoperative chemotherapy significantly improved
survival of patients with gastrointestinal lymphoma. Our
finding was similar to them. But the patients in most
studies (including ours) were not randomized to treat-
ment as part of a clinical trial, so there were some pos-
sible confounding factors. For example, older or sicker
patients were not candidates for chemotherapy. We con-
sider that randomized control trial should be performed
to assess the therapeutic outcomes.
Several recent studies showed that R-CHOP signifi-
cantly improves the clinical outcome of patients with
DLBCL [19-22]. In a retrospective study by Nyman et al
[23], they found that the additional benefit of R-CHOP
extended only to patients with non-GCB DLBCL and not
those with GCB DLBCL. In addition, Nyman et al did not
find a difference in survival between GCB and non-GCB
subtypes in the post-rituximab era, which implies that the
addition of rituximab eliminates the prognostic signifi-
cance of the classification of DLBCL. In a current study,
the survival rate of patients treated with R-CHOP chemo-
therapy was significantly longer than that to patients trea-
ted with CHOP. And in the non-GCB group, the survival
rate of patients treated with R-CHOP was significantly
longer than those with CHOP. In the GCB group, R-
CHOP chemotherapy also seemed to be an advantage (5
patients receiving R-CHOP chemotherapy survived). But
it was not found to be statistically significant between
patients receiving R-CHOP and CHOP therapy. These
results implied that the immunophenotype was useful in
predicting prognosis as well as selecting the most eco-
nomical, effective and reasonable chemotherapy regime.
R-CHOP chemotherapy is an advisable choice to patients
of non-GCB subtype, which can overcome the adverse
effects of this subtype. And if the patient’s economic con-
ditions permit, R-CHOP is also the first choice to patients
of GCB subtype who can also be treated with CHOP
alone. However, because our study is retrospective and
the patient population is small (especially the cases trea-
ted with R-CHOP therapy in GCB group may be not
enough), further studies need to be performed on a larger
patient population with primary gastrointestinal DLBCL
to confirm the results.
Conclusions
From our results we can conclude that the immunophe-
notype classification of gastrointestinal DLBCL, which isclosely related to local lymph node metastasis, is found
to have prognostic significance. Immunophenotype clas-
sification is also useful in selecting the chemotherapy
protocol.
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